Healthcare super fund HESTA directly invests in Inventia Life Science

1 June 2022 — Inventia Life Science, a startup biotech that develop, manufacture and distribute world-wide the most advanced, and award winning, RASTRUM™ 3D bioprinter, has today announced that HESTA have invested AU$4.4 million in Inventia Life Science. The bioprinter enables the scale up production of 3D cell cultures for research.

This investment is part of a successful Series B fundraise led by Blackbird Ventures with significant reinvestment from Skip Capital, which raised AU$35 million. This latest investment brings Inventia’s total funding to date to over AU$50 million. 

This marks the first direct investment made by a super fund and supports the wave of super funds investing in early-stage start-ups that represent innovative new industries which will drive economic jobs and growth.

Dr Julio Ribeiro, Founder and CEO of Inventia said:

We are delighted to partner with one of the leading institutional investors in Australia. This additional investment will provide critical support to drive the commercialisation of RASTRUM™ and expansion into the US market. Furthermore, this investment will hopefully encourage other super funds to engage with Australia’s growing and thriving start-up scene.” 

HESTA Chief Investment Officer Sonya Sawtell-Rickson said:

HESTA is excited to invest in Inventia as part of our broader focus on identifying investment opportunities in health technology and innovation. Through this partnership with Inventia, our members are invested in a company developing breakthrough bioprinting technology, enabling life-changing biomedical research and therapies. Investments like this support innovative start-ups at an early stage of their growth, which can deliver strong returns for members while having a positive impact on the world they will retire into.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Inventia Life Science. (2022, August 16). Healthcare super fund HESTA directly invests in Inventia Life Science. AZoLifeSciences. Retrieved on July 21, 2024 from https://www.azolifesciences.com/news/20220816/Healthcare-super-fund-HESTA-directly-invests-in-Inventia-Life-Science.aspx.

  • MLA

    Inventia Life Science. "Healthcare super fund HESTA directly invests in Inventia Life Science". AZoLifeSciences. 21 July 2024. <https://www.azolifesciences.com/news/20220816/Healthcare-super-fund-HESTA-directly-invests-in-Inventia-Life-Science.aspx>.

  • Chicago

    Inventia Life Science. "Healthcare super fund HESTA directly invests in Inventia Life Science". AZoLifeSciences. https://www.azolifesciences.com/news/20220816/Healthcare-super-fund-HESTA-directly-invests-in-Inventia-Life-Science.aspx. (accessed July 21, 2024).

  • Harvard

    Inventia Life Science. 2022. Healthcare super fund HESTA directly invests in Inventia Life Science. AZoLifeSciences, viewed 21 July 2024, https://www.azolifesciences.com/news/20220816/Healthcare-super-fund-HESTA-directly-invests-in-Inventia-Life-Science.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Australian company accelerating the speed of drug discovery wins prestigious Eureka prize